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SUMMARY
The lean diabetic patients with heart failure with preserved ejection fraction (HFpEF) in Asia suffer from adverse clinical outcomes and poor life quality. The suitable animal models are urgently needed for mechanistic study and therapeutic innovations. Our study reports that lipodystrophic mice with seipin depletion are lean, diabetic, and recapitulate major manifestations of clinical HFpEF, thereby clarifying that lean diabetes per se may produce HFpEF characteristics. We further demonstrate that increased cardiac titin phosphorylation and reactive interstitial fibrosis associated with neutrophil extracellular traps lead to left ventricular stiffness and suggest that both pathways may be potential therapeutic targets in Asian HFpEF patients. H eart failure with preserved ejection fraction (HFpEF) has been described as the greatest unmet need in cardiovascular medicine today (1) . It constitutes the dominant form of HF in aging societies, is the top cause of hospitalization among elderly persons worldwide, and carries a dismal prognosis with >50% 5-year mortality (2) . Outcomes have not been improved over the last decades, and there is currently still no effective therapy proven to improve survival in HFpEF (2) . There is an urgent need to better understand the pathophysiology of HFpEF and identify potential novel therapeutic targets (3) .
HFpEF represents a broad cohort of patients with a range of comorbidities, such as hypertension, obesity, and diabetes, that requires individualized management based on biological phenotypes (4, 5) . However, recent epidemiologic data from Asia suggest a unique lean diabetic phenotype of HFpEF, compared with other HF phenotypes, has the worst quality of life, more severe signs and symptoms of HF, and the highest rate of adverse clinical outcomes (6) (7) (8) .
A critical obstacle to therapeutic innovation in HFpEF has been the absence of suitable animal models that accurately recapitulate the complexities of the human disease (9, 10) . An ideal HFpEF animal model that captures 2 or more HFpEF features (e.g., Lipodystrophies are clinical disorders characterized by the selective loss of adipose tissue and severe insulin resistance, leading to diabetes (11, 12) .
Notably, the common cardiac abnormality, hypertrophic cardiomyopathy, occurs with considerable frequency in cohort patients with lipodystrophy caused by different genetic defects (13) (14) (15) . Patients carrying Berardinelli-Seip congenital lipodystrophy-2 (BSCL2)/ seipin mutation exhibit the most severe lipodystrophic phenotype (11, 16) , and they are lean, diabetic, and exhibit left ventricular (LV) hypertrophy without reduction of EF (13, 15) . The mechanisms underlying these cardiac manifestations remain poorly understood.
In the current study, we aimed to study whether aged seipin knockout (SKO) mice may serve as a validated model of lean diabetic HFpEF and to investigate potential pathophysiologic pathways underlying LV structural-functional abnormalities in the model.
METHODS
MICE AND STUDY DESIGN. The generation of SKO and littermate control (Ctrl) mice was described previously (17) . The timeline to investigate the metabolic, cardiac, and exercise characteristics of male mice is shown in Figure 1A was published previously (8, 18, 19) . The ethics approvals, study definitions, clinical outcomes, echocardiography, and imaging collection were described in detail (8) . In the current study, we further analyzed and compared data from lean diabetic HFpEF patients and age-matched control subjects without HF from the community. Figure 1B) . The adult SKO mice (18 to 24 weeks old) showed significantly elevated blood glucose and serum insulin levels under basal feeding ( Figure 1C) , which also displayed glucose intolerance and reduced insulin sensitivity (17) .
Moreover, we observed cardiomegaly in adult SKO mice (7.7 vs. 4.3 mg/g of body weight for SKO vs. Ctrl mice, w24 weeks old) ( Figure 1D ). The ratios of LV, left atrial (LA), and right atrial weight to body weight were significantly higher in SKO mice ages 41 to 46 weeks than in Ctrl mice of similar ages ( Figure 1E ). To clarify whether cardiomegaly was caused by the seipin mutation in mouse heart tissues, we first profiled Bscl2 messenger ribonucleic acid level in mouse tissues. In Ctrl mice, the Bscl2 gene was abundantly expressed in adipose tissues. By contrast, its expression level was the lowest in mouse hearts and muscles (Supplemental Figure 1A ). As expected, Bscl2 expression was not detectable in SKO mouse tissues (Supplemental Figure 1A ). We then established cardiomyocytespecific SKO. We did not observe any difference in terms of ratios between heart tissue weight and tibia length, including LV, LA, right ventricular, and right atrial tissues, between cardiomyocyte-specific SKO mice ages 55 to 60 weeks and corresponding Ctrl mice of similar ages (Supplemental Figure 1B) . These data suggest that cardiac abnormalities of SKO mice were unlikely to be the result of seipin mutation in mouse hearts, but were more likely due to systematic factors (e.g., hyperglycemia).
SKO MICE EXHIBIT LV CONCENTRIC HYPERTROPHY
WITHOUT HYPERTENSION. We performed echocardiography in the SKO and Ctrl mice and found thickened LV walls and increased LV mass, that is, cardiac hypertrophy in the SKO mice. These differences became even more prominent with aging ( Figure 2A) . We assessed both components of LV diastolic Lean Diabetic Mouse Model of HFpEF Lean Diabetic Mouse Model of HFpEF myocardium, comparing between SKO and Ctrl mice (Supplemental Figure 3 ). We then examined titin phosphorylation-a crucial mechanism responsible for increased myocardial stiffness in clinical HFpEF (25) . We used quantitative mass spectrometry to regulation of Il6 via toll-like receptor 2/4 in atherosclerosis (44) . In the myocardium, the cytokines further amplify their actions primarily through the activation of JAK-STAT3 signaling. STAT3 is a ubiquitous stress-activated transcription factor that regulates gene programs important for hypertrophy, fibrosis, and inflammation (45) . On cytokine binding to the specific receptors, STAT3 is phosphorylated and activated by JAK2 and then plays a crucial role in the induction of hypertrophic genes (21, 22, 46) . Our findings show that SKO mice have cardiac inflammation, along with activated STAT3 signaling and induction of Nppa and Acta1, thus supporting the current recognition that comorbidity-driven inflammation contributes to the cardiac hypertrophy and adverse outcomes (47) . As such, we suggest that NET may be a potential therapeutic target to intervene in inflammatory and fibrotic damage of SKO hearts. The activated peptidyl arginine deiminase 4 (PADI4) promotes citrullination of histone and allows decondensation of chromatin, a critical step for NET formation (33) . PADI4 inhibitor (Cl-amidine) blocks NET formation and is successfully used to reduce atherosclerosis burden (48) and rescue wound healing in diabetic mice (49) . It is of significant interest to examine whether Cl-amidine treatment produces beneficial effects on our HFpEF mice in a future study. 
